DALLAS, Sept. 29, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Avanir Pharmaceuticals (Nasdaq:AVNR). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Avanir Pharmaceuticals (Nasdaq:AVNR) should be of particular interest to other companies in the healthcare industry, particularly in the biotechnology and drug sector: Bristol-Myers Squibb Co. (NYSE:BMY), Eli Lilly & Co. (NYSE:LLY), GlaxoSmithKline (NYSE:GSK) and Amgen Inc. (Nasdaq:AMGN).
The full report is available at: http://www.stockpreacher.com/n/AVNR
Avanir Pharmaceuticals (AVNR) is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company's product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in phase III clinical development for the treatment of pseudobulbar affect and diabetic peripheral neuropathic pain. The Company's first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an FDA-approved over-the-counter treatment for cold sores.
In the report, the analyst notes:
"Potential revenue-generating contracts that remained active as of June 30, 2009, include several docosanol 10% cream license agreements, including the license agreement with GSK, potential royalties from our agreement with Azur Pharma and our license agreement with Novartis for our MIF technology. The Company said it may continue to seek partnerships with pharmaceutical companies that can help fund its operations in exchange for sharing in the success of any licensed compounds or technologies.
"AVNR recently announced that a reformulated version of its Zenvia drug reduced emotional outbursts tied to a neurological disorder, meeting the main goal of a late-stage study and nearly doubling the tiny company's stock price. The results in the STAR clinical trial come nearly three years after the U.S. Food and Drug Administration dealt the Company a blow by expressing safety concerns and asked the company to perform new trials with a reformulated version of Zenvia."
To read the entire report visit: http://www.stockpreacher.com/n/AVNR
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.